For example, in models of melanoma and non-small cell lung cancer (NSCLC), the combination of LDH inhibitors with PD-1/PD-L1 inhibitors has shown synergistic effects, resulting in improved anti-tumor responses compared to either therapy alone. Here, CD274 is linked to melanoma.